Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2) (DELTA 2)

  • End date
    Jan 2, 2023
  • participants needed
  • sponsor
    LEO Pharma
Updated on 14 June 2022


This is a 16-week study in adult participants with chronic hand eczema (CHE). The participants will visit the clinic regularly to have the study doctor assess their CHE and to answer questions about itch, pain, CHE symptoms, and quality of life.

The purpose is to assess how delgocitinib cream works to treat CHE when compared to a placebo cream with no active substance.

Condition Chronic Hand Eczema
Treatment Cream vehicle, Delgocitinib cream
Clinical Study IdentifierNCT04872101
SponsorLEO Pharma
Last Modified on14 June 2022


Yes No Not Sure

Inclusion Criteria

Diagnosis of CHE, defined as hand eczema that has persisted for more than 3 months or returned twice or more within the last 12 months
Disease severity graded as moderate to severe at screening and baseline according to IGA-CHE (i.e. an IGA-CHE score of 3 or 4)
HESD itch score (weekly average) of ≥4 points at baseline
Participants who have a documented recent history of inadequate response to treatment with topical corticosteroids (TCS) or for whom TCS are documented to be otherwise medically inadvisable (e.g. due to important side effects or safety risks)
Participants adherent to standard non-medicated skin care including avoidance of known and relevant irritants and allergens

Exclusion Criteria

Concurrent skin diseases on the hands, e.g. tinea manuum
Active atopic dermatitis requiring medical treatment in regions other than the hands and feet
Active psoriasis on any part of the body
Hyperkeratotic hand eczema in combination with a history of psoriasis on any part of the body
Clinically significant infection on the hands
Systemic treatment with immunosuppressive drugs, immunomodulating drugs, retinoids, or corticosteroids within 28 days prior to baseline
Use of tanning beds, phototherapy, or bleach baths on the hands within 28 days prior to baseline
Previous or current treatment with Janus kinase (JAK) inhibitors (including delgocitinib/LEO 124249), systemic or topical
Cutaneously applied treatment with immunomodulators or TCS on the hands within 14 days prior to baseline
Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 14 days prior to baseline
Other transdermal or cutaneously applied therapy on the hands (except for the use of subject's own emollients) within 7 days prior to baseline
Cutaneously applied treatments in regions other than the hands, which could interfere with clinical trial evaluations or pose a safety concern within 7 days prior to baseline
Treatment with any marketed biological therapy or investigational biologic agents
Any cell-depleting agents: within 6 months prior to baseline, or until lymphocyte count returns to normal, whichever is longer
Other biologics: within 3 months or 5 half-lives, whichever is longer, prior to baseline
Clinically significant infection within 28 days prior to baseline which, in the
History of any known primary immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test at screening, or the participant taking antiretroviral medications as determined by medical history and/or participant's verbal report
opinion of the investigator, may compromise the safety of the participant in
Any disorder which is not stable and could
the trial, interfere with evaluation of the IMP, or reduce the participant's
Affect the safety of the participant throughout the trial
ability to participate in the trial
Impede the participant's ability to complete the trial
Positive hepatitis B surface antigen or hepatitis C virus antibody serology at
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note